Tower Research Capital LLC (Trc) Esperion Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,711 shares of ESPR stock, worth $14,227. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,711

Holding current value

$14,227

% of portfolio

0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.61 - $2.73 $10,804 - $18,321	6,711 New	6,711 $11,000
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $45,597 - $68,170	22,573 Added 235.14%	32,173 $86,000
Q4 2023 Feb 13, 2024	SELL	$0.73 - $3.08 $40,817 - $172,215	-55,914 Reduced 85.35%	9,600 $28,000
Q3 2023 Nov 14, 2023	BUY	$0.96 - $1.79 $41,441 - $77,270	43,168 Added 193.18%	65,514 $64,000
Q2 2023 Aug 14, 2023	BUY	$1.2 - $1.76 $1,726 - $2,532	1,439 Added 6.88%	22,346 $31,000
Q1 2023 May 09, 2023	BUY	$1.46 - $7.3 $20,340 - $101,703	13,932 Added 199.74%	20,907 $33,000
Q4 2022 Feb 10, 2023	SELL	$5.09 - $8.5 $67,646 - $112,965	-13,290 Reduced 65.58%	6,975 $43,000
Q3 2022 Nov 10, 2022	BUY	$5.45 - $8.13 $94,388 - $140,803	17,319 Added 587.88%	20,265 $136,000
Q2 2022 Aug 15, 2022	SELL	$4.77 - $6.67 $19,046 - $26,633	-3,993 Reduced 57.54%	2,946 $19,000
Q1 2022 May 12, 2022	BUY	$3.34 - $5.56 $16,897 - $28,128	5,059 Added 269.1%	6,939 $32,000
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $34,410 - $85,275	-7,154 Reduced 79.19%	1,880 $9,000
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $71,362 - $134,481	6,293 Added 229.59%	9,034 $109,000
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $19,885 - $29,427	1,025 Added 59.73%	2,741 $58,000
Q1 2021 May 17, 2021	BUY	$25.12 - $36.89 $26,275 - $38,586	1,046 Added 156.12%	1,716 $49,000
Q4 2020 Feb 16, 2021	SELL	$24.2 - $35.76 $38,574 - $57,001	-1,594 Reduced 70.41%	670 $17,000
Q3 2020 Nov 16, 2020	SELL	$31.18 - $52.71 $172,924 - $292,329	-5,546 Reduced 71.01%	2,264 $84,000
Q2 2020 Aug 13, 2020	BUY	$30.04 - $51.31 $234,612 - $400,731	7,810 New	7,810 $401,000
Q1 2020 May 15, 2020	SELL	$27.44 - $73.84 $37,345 - $100,496	-1,361 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$35.4 - $59.82 $8,425 - $14,237	238 Added 21.19%	1,361 $81,000
Q3 2019 Nov 05, 2019	BUY	$34.47 - $47.53 $38,709 - $53,376	1,123 New	1,123 $42,000
Q2 2019 Aug 13, 2019	SELL	$40.1 - $52.33 $22,576 - $29,461	-563 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$40.11 - $53.57 $12,313 - $16,445	307 Added 119.92%	563 $23,000
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $9,469 - $15,132	256 New	256 $12,000
Q3 2018 Nov 13, 2018	SELL	$40.74 - $51.41 $39,191 - $49,456	-962 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$36.2 - $76.4 $30,770 - $64,940	850 Added 758.93%	962 $38,000
Q1 2018 May 15, 2018	SELL	$65.94 - $80.76 $12,792 - $15,667	-194 Reduced 63.4%	112 $8,000
Q4 2017 Feb 09, 2018	BUY	$43.47 - $67.43 $13,301 - $20,633	306	306 $20,000

Others Institutions Holding ESPR

# of Institutions

208

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $141M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Esperion Therapeutics, Inc. Transaction History